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The large GTPase Dynamin 2 (Dyn2) is markedly up-
regulated in pancreatic cancer, is a potent activator
of metastatic migration, and is required for Rac1-
mediated formation of lamellipodia. Here we demon-
strate an unexpected mechanism of Dyn2 action in
these contexts via direct binding to the Rac1 guanine
nucleotide exchange factor (GEF) Vav1. Surprisingly,
disruption of the Dyn2-Vav1 interaction targets Vav1
to the lysosome for degradation via an interaction
with the cytoplasmic chaperone Hsc70, resulting in
a dramatic reduction of Vav1 protein stability. Impor-
tantly, a specific mutation in Vav1 near its Dyn2-
binding C-terminal Src homology 3 (SH3) domain
prevents Hsc70 binding, resulting in a stabilization
of Vav1 levels. Dyn2 binding regulates the interaction
of Vav1 with Hsc70 to control the stability and subse-
quent activity of this oncogenic GEF. These findings
elucidate how Dyn2 activates Rac1, lamellipod
protrusion, and invasive cellular migration and
provide insight into how this specific Vav is ectopi-
cally expressed in pancreatic tumors.
INTRODUCTION
Invasive cell migration is a crucial process that is required
throughout development and is aberrantly upregulated in tumor
cells, promoting cancer metastasis. Pancreatic cancer is the
fourth leading cause of cancer death in the United States, owing
primarily to late detection and a high incidence of metastasis.
Upon diagnosis, these tumors have very often actively dissemi-
nated to a variety of different organs, resulting in an exceptionally
low 5-year survival rate of 5% (Jemal et al., 2010).
Several cytoskeletal proteins are aberrantly regulated in
pancreatic cancers and correlate with increased tumor burden
(Kikuchi et al., 2008; Matsuda et al., 2011; Ni et al., 2008;
Wang et al., 2010; Welsch et al., 2007). We previously reported
that the large GTPase Dynamin 2 (Dyn2) is elevated in the
majority of human pancreatic adenocarcinomas, and that theseDeveloelevated levels support increased lamellipodial extension, cell
migration, and invasion in vitro, and dissemination to distal
organs in vivo using orthotopic mouse models (Eppinga et al.,
2012). Conventional dynamins are well known for their role in
the endocytic process and function as pinchases to liberate
newly forming endocytic pits (Doherty andMcMahon, 2009; Hin-
shaw, 2000). This versatile family of mechanoenzymes also func-
tions in endosomal trafficking, Golgi dynamics, and cytoskeletal
regulation (Gu et al., 2010; Jones et al., 1998; McNiven et al.,
2000a; Mooren et al., 2009; Schroeder et al., 2010). How
elevated Dyn2 levels potentiate invasive properties is not under-
stood, although this enzyme has been implicated in regulating
focal adhesion dynamics (Ezratty et al., 2005; Wang et al.,
2011) and the assembly of branched actin networks that may
facilitate lamellipodial extension (Kruchten and McNiven, 2006;
Schafer, 2004).
Rac1 is a small GTPase that cycles between an active, guano-
sine triphosphate (GTP)-bound form and an inactive, guanosine
diphosphate (GDP)-bound form. This cycle is regulated by acti-
vating guanine nucleotide exchange factors (GEFs) and inacti-
vating GTPase activating proteins (GAPs). Active Rac1 signals
downstream to regulate actin dynamics and branching, and
induce the formation of lamellipodia (Ridley, 2011). Schlunck
et al. (2004) demonstrated that Dyn2 regulates the localization
of active Rac1, without affecting its activation, by regulating its
internalization and trafficking to promote the formation of lamel-
lipodia. However, how these distinct GTPases, the large mecha-
noenzyme Dyn2, and the small regulatory switch Rac1 might
interact structurally or functionally remains undefined. One
important study showed that the Rac1 GEF Vav1 interacts
directly with Dyn2 in T cells (Gomez et al., 2005).
Vav1 is a 95 kDa exchange factor that is regulated by phos-
phorylation and has been proposed to serve adaptor functions
through conserved Src homology 2 (SH2) and SH3 domains
(Bustelo, 2001; Lazer et al., 2010; Turner and Billadeau, 2002).
Vav1 expression is normally restricted to hematopoietic cells,
where it plays an essential role in the development and activation
of T cells by modulating transcription and the cytoskeleton (Ty-
bulewicz, 2005). However, Vav1 has also been defined as an
oncogene, as deletion of the regulatory amino terminal region
or mutation of regulatory tyrosine phosphorylation site Tyr174
results in transformation of fibroblasts (Katzav et al., 1989; Lo´-
pez-Lago et al., 2000). Critically, more recent findings thatpmental Cell 24, 573–585, March 25, 2013 ª2013 Elsevier Inc. 573
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cancer cell lines strengthens the argument that Vav1 may be
a key driver of oncogenic transformation and tumor progression.
Vav1 is aberrantly expressed in several human cancer types,
including neuroblastoma, melanoma, lung cancer, and breast
cancer (Bartolome´ et al., 2006; Hornstein et al., 2003; Katzav,
2009; Lazer et al., 2009). Of most relevance, Fernandez-Zapico
et al. (2005) reported that Vav1 is ectopically expressed in
>50% of pancreatic ductal adenocarcinomas, where it regulates
cell-cycle progression through cyclin D1 expression to promote
cell survival, proliferation, and transformation of cultured pancre-
atic cancer cells; however, they did not examine a possible link to
migratory invasion.
Because Dyn2 and Vav1 are both upregulated in human
pancreatic cancers and are known to interact in hematopoietic
cells, we hypothesized that Vav1 could link Dyn2 to Rac1 activa-
tion to promote migration of pancreatic tumor cells. Here, we
demonstrate that Dyn2 and Vav1 associate in pancreatic cancer
cells and not only promote but are essential for Rac1 activation,
lamellipodial extension, and invasive cell migration. Most inter-
estingly, we found that Dyn2 binding is essential for Vav1 protein
stability, as a reduction in Dyn2 levels is paralleled by a near-
complete cellular loss of Vav1 and leads to its accumulation in,
and subsequent degradation by, the lysosome. We identified
an interaction between Vav1 and the chaperone Hsc70 that
directs Vav1 to the lysosome for degradation and is regulated
by the direct binding of Dyn2 to Vav1. These findings define
a functional relationship between a large contractile GTPase
and activation of the small GTPase Rac1 to potentiate pancreatic
tumor cell invasion.
RESULTS
Dyn2 Is Required for Rac1-Dependent Pancreatic
Cancer Cell Migration
The large GTPase Dyn2 is overexpressed in pancreatic tumors
and promotes enhanced cancer cell migration and invasion (Ep-
pinga et al., 2012), though how Dyn2 participates in this invasive
process is unknown. In this study, we utilized four different
pancreatic adenocarcinoma cell lines that possess distinct
features and advantages as experimental models. Panc04.03
cells are highly motile and provide an excellent model system
for studying migration. HPAF-II cells form large, stable lamellipo-
dia at a high frequency following acute epidermal growth factor
(EGF) stimulation and thus can be quantitatively measured for la-
mellipod formation. DanG and Panc04.03 are easily manipulated
for biochemical studies. Importantly, DanG, Panc04.03, and
HPAF-II cells are all positive for expression of the GEF Vav1,
as described below. Finally, Panc1 cells do not express Vav1
and thus provide an excellent model system for studying the
effects of ectopic expression of Vav1 on signaling, lamellipod
formation, and cell migration.
We studied the role of Dyn2 in cell migration using a transwell
chemotactic cell migration assay. Consistent with our previous
report (Eppinga et al., 2012), silencing of Dyn2 in Panc04.03
pancreatic adenocarcinoma cells by small interfering RNA
(siRNA) resulted in a significant decrease in transwell cell migra-
tion (Figure 1A). Because formation of lamellipodia is an impor-
tant component of migration, we tested whether lamellipod574 Developmental Cell 24, 573–585, March 25, 2013 ª2013 Elsevierformation and extension were defective following Dyn2 knock-
down. HPAF-II pancreatic tumor cells were transfected with
either control siRNA or siRNA to Dyn2, and the cells were stimu-
lated with EGF (100 ng/ml) for 20 min to induce the formation of
lamellipodia. Depletion of Dyn2 resulted in a 50%decrease in the
percentage of cells that formed lamellipodia, consistent with
previous reports (Figure 1B; Schlunck et al., 2004).
Because Rac1 activation is critical for the extension of lamel-
lipodia, and both Dyn2 and Rac1 have been implicated in tumor
cell migration, we hypothesized that Rac1 activation was
impaired as a result of Dyn2 knockdown. Therefore, we pre-
dicted that overexpression of constitutively active Rac1 could
rescue the defect in lamellipod formation in Dyn2 knockdown
cells. Indeed, expression of Rac1-V12 completely restored the
formation of lamellipodia in HPAF-II cells depleted of Dyn2 (Fig-
ure 1C), suggesting that Rac1 activation is downstream of
Dyn2. To test this prediction biochemically, we depleted Dyn2
using siRNA in Panc04.03 cells and assessed Rac1 activation
by a glutathione S transferase (GST) pull-down assay using
the p21-binding domain (PBD) of p21-activated kinase 1
(PAK1), which binds only GTP-bound, active Rac1. Interest-
ingly, Rac1 activation was decreased by >50% following
siRNA-mediated depletion of Dyn2 (Figure 1D). Together, these
data suggest that Dyn2 potentiates lamellipod formation and
migration of pancreatic cancer cells by promoting the activation
of Rac1.
Dyn2 Binds the Rac1 GEF Vav1 in Pancreatic Cancer
Cells
Based on the observations described above, we predicted that
Dyn2 could either promote the activity of a Rac1-activating
GEF or inhibit the activity of a Rac1-inactivating GAP. It has
been shown in T cells that Dyn2 interacts with the Rac1 GEF
Vav1 (Gomez et al., 2005). Vav1 is normally expressed in hema-
topoietic cells and not in normal epithelial cells, but it was shown
to be ectopically expressed in >50% of pancreatic cancers and
in multiple pancreatic cancer cell lines (Fernandez-Zapico et al.,
2005; Figure S1A available online), where it was implicated in
cell-cycle regulation. Because Dyn2 is also overexpressed in
pancreatic cancers, we predicted that Vav1 could be a link
between Dyn2 and Rac1 in pancreatic cancer cells.
Using coimmunoprecipitation, we found that endogenous
Vav1 and Dyn2 associate in pancreatic cancer cells (Figure 2A).
It was previously reported that the Dyn2-Vav1 interaction is
mediated by the proline-rich domain (PRD) of Dyn2, and the
C-terminal SH3 domain of Vav1 (Figure 2B; Gomez et al.,
2005). GST pull-down experiments in the tumor cell lines
confirmed that the purified Vav1 SH3 domain interacts with
full-length Dyn2, and this interaction was inhibited by deletion
of residues 800–811 within the Dyn2 PRD (D800–811; Figure 2C).
Disruption of the Vav1 SH3 by mutation (WW820/821YY)
blocked the capacity to pull down Dyn2, demonstrating that an
intact SH3 domain is required for Vav1/Dyn2 binding (Figure 2D).
To confirm that the Dyn2-Vav1 interaction is direct, we tested the
interaction between the purified Vav1 SH3 and the purified, His-
tagged Dyn2 PRD. We observed that the Dyn2 PRD bound
strongly to GST-Vav1-SH3, and that mutating the Vav1 SH3
domain (WWYY) blocked this interaction (Figure 2E). Similar
results were observed using purified full-length Dyn2 (data notInc.
Figure 1. Dyn2 Promotes Pancreatic Cancer Cell Migration through Activation of Rac1
(A) Panc04.03 cells seeded in a transwell assay were incubated for 16 hr, counted by DAPI stain, and normalized to siRNA-transfected controls.
(B) HPAF-II cells were serum starved and then stimulated with EGF (50 ng/ml) for 20 min and stained for cortactin to show lamellipodia (arrows); n > 100 cells per
experiment.
(C) HPAF-II cells were transfected with GFP-Rac1-V12 or GFP vector alone and then treated as in (B). Asterisks indicate transfected cells.
(D) Panc04.03 cells were subjected to a GST-PBD pull-down assay for active Rac1 and immunoblotted for the indicated proteins. Active Rac1 levels were
normalized to actin; this ratio was normalized to control siRNA-transfected cells.
Cells were depleted of Dyn2 by siRNA transfection. Scale bars, 10 mm. All graphs represent the mean ± SEM of at least three independent experiments. *p < 0.05,
**p < 0.01.
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pancreatic cancer cells.
In independent studies, both Dyn2 and Vav1 proteins have
been shown to localize to the leading edge of migrating cells
(McNiven et al., 2000b; Miranti et al., 1998). To determine
whether these interacting proteins colocalize in cells, we trans-
fected Panc1 cells with Vav1 and assessed Vav1 and Dyn2 local-
ization by immunofluorescence. We observed that both proteins
localize to the lamellipodia (Figure 2F) and share similar
membrane domains within these extensions, in support of the
immunoprecipitation data described above.
Expression of Vav1 in pancreatic tumor cells enhances
survival, proliferation, and oncogenic transformation (Fernan-
dez-Zapico et al., 2005). In addition, in T cells, Vav1 is a known
regulator of spreading and induction of lamellipodia during integ-
rin engagement (del Pozo et al., 2003). Because Vav1 is a known
activator of Rac1, a central player in cell migration, we hypothe-
sized that Vav1 could also promote the migration of pancreatic
tumor cells. To examine this issue, we determined the effects
of Vav1 on Rac1 activation, lamellipod formation, and chemo-
tactic cell migration. Depletion of Vav1 expression using siRNA
inhibited Rac1 activation in DanG cells by 50% (Figure 3A),
a finding that was not necessarily anticipated, as most migratoryDeveloepithelial cells do not express Vav1. Based on this observation,
as well as the lamellipodial localization of Vav1 in Figure 2F, we
predicted that Vav1-dependent Rac1 activation could enhance
the formation of lamellipodia in the tumor cells expressing this
GEF. Indeed, siRNA-mediated depletion of Vav1 in HPAF-II cells
blocked the formation of lamellipodia (Figure 3B), as well as the
related process of spreading on a fibronectin substrate (Fig-
ure S1B). Knockdown of Vav1 also significantly inhibited chemo-
tactic migration through a transwell chamber by 70% (Figure 3C)
and inhibited migration in a wound-healing assay (Figures S1C
and S1D). These data indicate that Vav1 is a potent activator
of pancreatic tumor cell migration.
Because Vav1 is ectopically expressed in many, but not all,
pancreatic cancer cell lines (Figure S1A), we tested whether
Vav1 overexpression in a tumor cell line that does not express
this GEF (Panc1 cells) could induce cell migration and lamellipod
formation. Panc1 cells were transfected with wild-type (WT)
Vav1 and stimulatedwith EGF (50 ng/ml, 20min) to induce lamel-
lipod formation. Overexpression of WT Vav1markedly increased
the percentage of cells capable of forming lamellipodia, but this
effect was blocked by expression of amutated Vav1 lacking GEF
activity (L278Q; Figure 3D). Strikingly, high levels of WT Vav1
were sufficient to induce massive lamellipodia and inducepmental Cell 24, 573–585, March 25, 2013 ª2013 Elsevier Inc. 575
Figure 2. Dyn2 Binds to Vav1 in the Lamellipodia of Pancreatic Cancer Cells
(A) DanG cells were immunoprecipitated for Vav1 and then immunoblotted for Dyn2 or Vav1. A longer exposure was needed to detect Vav1 in the input.
(B) Cartoons showing the domain structure of Dyn2 and Vav1. Dyn2 includes a GTPase domain, a middle domain, a plekstrin homology domain (PH), a GTPase
effector domain (GED), and a PRD. Vav1 contains a calponin homology domain (CH), an acidic domain (Ac), a Dbl homology domain (DH), a PH, a zinc finger (ZF),
two SH3 domains, and an SH2 domain. Mutations used throughout the study (Dyn2 D800-811 and Vav1 WWYY) are indicated.
(C) MiaPaCa2 cells were transfected with GFP, GFP-Dyn2, or GFP-Dyn2 D800-811, and lysates were precipitated using purified GST-Vav1-SH3.
(D) Endogenous Dyn2 from MiaPaCa2 cell lysate coprecipitated with purified GST-Vav1-SH3, but not when the SH3 domain was mutated (WWYY).
(E) Purified His-Dyn2 PRD was precipitated with purified GST-Vav1-SH3, indicating that Dyn2 and Vav1 interact directly.
(F) Panc1 cells were transfectedwith Vav1 and then stained for Vav1 (red) and endogenous Dyn2 (green). The intensity of antibody staining was quantified over the
white bar and is plotted in the lower panel. AFU, arbitrary fluorescence units.
Scale bars, 10 mm. See also Table S1.
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stimulation (Figure 3D), demonstrating that Vav1 is a potent acti-
vator of cell migration in these tumor cells through its exchange
factor activity.
A Dyn2-Vav1 Interaction Promotes Rac1 Activation,
Lamellipod Formation, and Cell Migration
Because Vav1 and Dyn2 are both required for maximal Rac1
activation and the formation of lamellipodia, we tested whether
the Dyn2-Vav1 interaction is important for Rac1 activation and
tumor cell migration. First, we stably transduced Panc04.03 cells
with a lentivirus expressing WT Dyn2 or Dyn2 D800-811, and
then tested Rac1 activation using a biochemical GST-PBD
pull-down. Overexpression of WT Dyn2 increased the amount576 Developmental Cell 24, 573–585, March 25, 2013 ª2013 Elsevierof active Rac1 nearly 2-fold, whereas Dyn2 D800-811, which
does not bind Vav1, inhibited Rac1 activation (Figure 4A). Next,
Panc1 cells, which do not express endogenous Vav1, were
transfected with WT Vav1 or Vav1 WWYY, which does not bind
Dyn2 (Figure 2). Importantly, overexpression of Vav1 potently
increased the levels of active Rac1, and this was completely in-
hibited by Vav1 WWYY (Figure 4B). These results demonstrate
that the Dyn2-Vav1 interaction promotes activation of Rac1.
To test whether this Rac1 activation translates into lamellipo-
dia formation, we expressed WT Dyn2 or Dyn2 D800-811 in
HPAF-II cells stimulated with EGF. Whereas expression of WT
Dyn2 modestly increased the percentage of cells forming lamel-
lipodia, Dyn2 D800-811 expression inhibited lamellipod forma-
tion (Figure 4C). Similarly, overexpression of WT Vav1 in Panc1Inc.
Figure 3. Vav1 Promotes Invasive Migration of Pancreatic Cancer Cells
(A) DanG cells were subjected to a GST-PBD pull-down for active Rac1. Active Rac1 was normalized to total Rac1 and ratios were normalized to control cells.
(B) HPAF-II cells were serum starved and then stimulated with EGF (50 ng/ml, 20 min) and stained for cortactin to show lamellipodia (arrows).
(C) Panc04.03 cells seeded in a transwell assay were incubated for 16 hr, counted by DAPI stain, and normalized to siRNA-transfected controls.
(D) Panc1 cells were transfected with a control vector (vec), WT Vav1, or GEF-inactive Vav1 (L278Q), and then serum starved. They were stimulated with EGF
(50 ng/ml, 20 min) and stained for actin to show lamellipodia (arrows) and Vav1 (not shown).
Cells were depleted of Vav1 by siRNA transfection (A–C). Asterisks indicate transfected cells. Scale bars, 10 mm. All graphs represent the mean ± SEM of three
independent experiments. *p < 0.05, **p < 0.01. See also Figure S1.
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response to EGF stimulation, but Vav1 WWYY inhibited lamelli-
pod formation (Figure 4D). These data indicate that the Vav1-
Dyn2 interaction promotes the formation of lamellipodia in
pancreatic cancer cells.
The biochemical and cell-biological observations described
abovewere extended to test the role of this interaction in chemo-
tactic transwell cell migration. Dyn2 was depleted in Panc04.03
cells by siRNA, and then WT Dyn2 or Dyn2 D800-811 was stably
re-expressed using a lentiviral expression system. Consistent
with the effects on lamellipod formation, re-expression of WT
Dyn2 potently enhanced chemotactic cell migration, but Dyn2
D800-811 inhibited this effect by 50% (Figure 4E). Similarly, tran-
sient overexpression of Vav1 in Panc1 cells markedly enhanced
chemotactic cell migration, whereas this effect was inhibited by
Vav1 WWYY (Figure 4F). Together, these data are consistent
with the premise that a Dyn2 interaction with the GEF Vav1 isDevelorequired to promote Rac1 activation and the subsequent forma-
tion of lamellipodia to support themigration of pancreatic cancer
cells.
Dyn2 Binding Regulates Vav1 Protein Stability
Given the potent effects of the Dyn2-Vav1 interaction on Rac1
activity and function, we sought to determine the mechanism
by which Dyn2-Vav1 binding regulates Rac1 activation and
tumor cell migration. Because Dyn2 has been implicated in regu-
lating Rac1 signaling through endocytic trafficking (Kawada
et al., 2009; Palamidessi et al., 2008; Schlunck et al., 2004), we
first hypothesized that Vav1 binding could regulate Dyn2 enzy-
matic activity or function in endocytosis. However, we observed
no inhibition of endocytosis in cells expressing Dyn2 D800-811,
as determined by measuring the uptake of labeled EGF (Fig-
ure S2A). Similarly, expression of Vav1 WWYY did not inhibit
EGF uptake compared with cells expressing WT Vav1pmental Cell 24, 573–585, March 25, 2013 ª2013 Elsevier Inc. 577
Figure 4. A Dyn2-Vav1 Interaction Promotes Rac1 Activation and Cell Migration
(A and B)WTDyn2 or Dyn2D800-811was stably overexpressed in Panc04.03 cells (A), andWT Vav1 or Vav1WWYYwas transiently overexpressed in Panc1 cells
(B). For expression of the Vav1 WWYY mutant, at least 10-fold higher amounts of cDNA were transfected compared with WT Vav1 to obtain comparable protein
levels by immunoblot. For both (A) and (B), lysates were subjected to a GST-PBD pull-down for active Rac1. Active Rac1 was normalized to total Rac1 and ratios
were normalized to vector-expressing control cells.
(C andD) HPAF-II cells were transfectedwith empty vector (vec),WTDyn2, or Dyn2D800-811 (C), and Panc1 cells were transfectedwith vector, WT Vav1, or Vav1
WWYY (D). For both (C) and (D), cells were serum starved and then stimulated with EGF (50 ng/ml, 20min) and stained for myc-Dyn2 or Vav1 (not shown) and actin
to show lamellipodia (arrows). Asterisks indicate transfected cells. Scale bars, 10 mm.
(E and F) Panc04.03 cells stably expressingWT Dyn2 or Dyn2 D800-811 were depleted of endogenous Dyn2 by siRNA (E), and Panc1 cells were transfected with
WT Vav1 or WWYY (F). For both (E) and (F), cells were seeded in transwell chambers and incubated for 16 hr, counted by DAPI staining, and normalized to control
cells. Two fields from three independent experiments were scored. All graphs represent the average ± SEM of three independent experiments. *p < 0.05,
**p < 0.01.
See also Figure S2.
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in Panc1 cells, which do not express Vav1, indicating that this
mutant protein can support endocytosis (Figure S2C). These
data suggest that the Dyn2-Vav1 interaction does not regulate
Dyn2 function in endocytosis, and that Dyn2 regulates Rac1 acti-
vation by a distinct mechanism.
Unexpectedly, when Dyn2 was depleted using siRNA, there
was a concomitant and significant (80%) reduction of Vav1
protein (Figure 5A). This effect was observed using multiple
siRNAs, using lentiviral-based shRNA depletion of Dyn2, and in
multiple cell lines (Figure S3A; data not shown), indicating the
loss of Vav1 protein is widespread and not due to an off-target
effect of siRNA-mediated knockdown of Dyn2. These findings578 Developmental Cell 24, 573–585, March 25, 2013 ª2013 Elsevierare exciting because they provide a potential explanation for
how the Dyn2-Vav1 interaction can regulate Rac1 activity. To
define how Dyn2 might affect the levels of Vav1 protein, we first
tested whether Dyn2 affects Vav1 transcription using RT-PCR.
We observed no change in Vav1 messenger RNA levels in cells
depleted of Dyn2 by siRNA, suggesting that Dyn2 regulates
Vav1 posttranscriptionally (Figure S3B). To test whether Vav1
protein stability was altered in the absence of Dyn2, we per-
formed a time course of cycloheximide (CHX) treatment to inhibit
new protein synthesis and to monitor turnover of endogenous
Vav1 in the presence or absence of endogenous Dyn2. Vav1
levels remained stable over the 6 hr time course in DanG cells
transfected with a control siRNA. However, in the absence ofInc.
Figure 5. Dyn2 Interaction Mediates Vav1 Protein Stability
(A) DanG cells were transfected with control siRNA or siRNA targeting Dyn2,
and Vav1 protein levels were normalized to actin.
(B) DanG cells were transfected with control siRNA (closed symbols) or siRNA
targeting Dyn2 (open symbols) and then treated with CHX (50 mg/ml) for 0–6 hr.
Vav1 levels were normalized to actin and compared with t = 0.
(C–G) Lysates were immunoblotted for the indicated proteins to determine the
effects on Vav1 levels. (C) Panc04.03 cells were depleted of Dyn2 using siRNA
and then transfected with GFP vector, GFP Dyn2, or GFP Dyn2 D800-811. (D)
Panc1 cells, which do not express Vav1, were transfected with equal amounts
of cDNA for WT Vav1 or Vav1 WWYY. (E) Panc04.03 cells were transfected
with siRNA to Dyn2 or control siRNA and then with empty GFP vector, WTGFP
Dyn2, or GFP-Dyn2-PRD. (F) DanG cells were transfected with GFP, GFP WT
Dyn2, or GFP Dyn2 K44A. (G) DanG cells were treated with DMSO, Dynasore
(80 mM), or MiTMAB (10 mM) for 24 hr.
Graphed values represent the mean ± SEM of three independent experiments;
**p < 0.001 (A and B). See also Figure S3.
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(Figure 5B).
These findings support the intriguing concept that Dyn2
protein levels affect Vav1 protein stability, possibly by a direct
structural interaction. To test this, we assessed Vav1 protein
levels upon disruption of Dyn2-Vav1 binding by depleting Dyn2
by siRNA and then re-expressing either WT Dyn2 or Dyn2
D800-811. Vav1 protein levels were completely rescued byDeveloexpression of GFP-tagged WT Dyn2, but not by re-expression
of GFP-Dyn2 D800-811 (Figure 5C). Similarly, the protein levels
of transiently transfected Vav1 WWYY were also dramatically
reduced compared with those ofWT Vav1, even though the tran-
script levels of WT Vav1 and Vav1 WWYY were nearly identical
(Figures 5D andS3C). Taken together, these results demonstrate
that Dyn2 binding regulates Vav1 protein turnover.
Because Dyn2-Vav1 binding is mediated by a PRD-SH3
interaction, and the PRD is sufficient to bind Vav1 (Figure 2),
we tested whether re-expression of the Dyn2 PRD alone was
sufficient to restore Vav1 protein levels in pancreatic cancer
cells depleted of Dyn2. Expression of the Dyn2 PRD did not
rescue Vav1 levels in Dyn2 knockdown cells (Figure 5E), indi-
cating that the SH3-PRD interaction alone is not sufficient to
stabilize Vav1. Further, the decrease in Vav1 protein stability
is not due to a loss of Dyn2 enzymatic activity, as expression
of dominant-negative Dyn2 (K44A) or treatment with the Dyn2
inhibitors Dynasore or MiTMAB had no effect on Vav1 protein
levels (Figures 5F, 5G, and S3D). Taken together, these data
indicate that Dyn2 binding is required to maintain Vav1 protein
stability.
Dyn2 Protects Vav1 from Lysosomal Degradation
We next sought to determine the mechanism by which Vav1 is
degraded in the absence of Dyn2 binding. Previous reports
have indicated that Vav1 can be ubiquitinated and degraded
by the proteasome (Bustelo et al., 1997; De Sepulveda et al.,
2000; Miura-Shimura et al., 2003). However, we were unable to
detect any ubiquitination of Vav1 in Dyn2 knockdown cells. Simi-
larly, treatment with the protease inhibitor MG132 did not
prevent Vav1 degradation when Dyn2 was depleted (Figures
S3E and S3F). Some cytoplasmic proteins can be targeted to
the lysosome for subsequent degradation. To test this possi-
bility, we inhibited lysosomal degradation by treating DanG cells
with chloroquine (CQ). Surprisingly, CQ treatment blocked the
degradation of Vav1 when Dyn2 was depleted by siRNA (Fig-
ure 6A). Similar results were obtained using NH4Cl to inhibit the
lysosome (Figure S3G), suggesting that Dyn2 protects Vav1
from lysosomal degradation.
To confirm that lysosomal targeting of Vav1 is regulated by the
Dyn2-Vav1 interaction,WT Vav1 or Vav1WWYYwas transfected
into Panc1 cells that were then treated with CQ. Again, this treat-
ment blocked the degradation of Vav1 WWYY (Figure 6B), indi-
cating that Vav1WWYY is degraded by the lysosome, consistent
with Dyn2 binding protecting Vav1 from lysosomal degradation.
To support these biochemical observations, we tested whether
Vav1 might associate with the lysosomal marker Lamp1.
Because our antibodies against Vav1 do not recognize endoge-
nous Vav1 by immunofluorescence, we transfected DanG cells
with mCherry-tagged WT Vav1 or Vav1 WWYY, along with
GFP-tagged Lamp1. Whereas mCherry-WT Vav1 showed
minimal colocalization with GFP-Lamp1, the mutant mCherry-
Vav1 WWYY protein showed significant accumulation within
the lumen of Lamp1-positive vesicles (Figure 6C). Consistent
with this finding, the lysosomal localization of Vav1 WWYY was
further enhanced by CQ treatment to inhibit lysosomal degrada-
tion. Taken together, these data support the concept that Dyn2
binding protects Vav1 from targeted degradation by the
lysosome.pmental Cell 24, 573–585, March 25, 2013 ª2013 Elsevier Inc. 579
Figure 6. Dyn2 Protects Vav1 from Degradation by the Lysosome
(A) DanG cells were transfected with a control siRNA or a siRNA against Dyn2 and treated with CQ (25 mM) for 48 hr. Vav1 protein levels were normalized to actin.
(B) Panc1 cells were transfected with WT Vav1 or Vav1 WWYY and then treated with 25 mM CQ for 48 hr. Vav1 protein levels were normalized to actin.
(C) DanG cells were cotransfected with mCherry Vav1 (WT or WWYY) and GFP-Lamp1 and incubated for 48 hr in the presence of CQ (25 mM). Representative
images show mCherry Vav1 WWYY accumulating in the lumen of GFP-Lamp1-positive vesicles (arrows). Yellow boxed areas in the left images are magnified at
right. Scale bar = 10 mm. The number of GFP-Lamp1-positive vesicles per cell containing mCherry Vav1 or mCherry Vav1 WWYY was counted (n > 25 cells per
experiment). Graphed data represent the mean number of vesicles ± SEM from three independent experiments. **p < 0.01.
Graphs represent the mean ± SEM of three independent experiments; *p < 0.05, **p < 0.001 (A and B).
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tion via an interaction with the chaperone protein Hsc70. Hsc70
binding directs cytoplasmic proteins to lysosomes via chap-
erone-mediated autophagy (CMA; Kaushik and Cuervo, 2012),
to late endosomes via endosomal microautophagy (Sahu et al.,
2011), and to autophagosomes for macroautophagy (Arndt
et al., 2010). Therefore, we tested whether Vav1 might interact
with Hsc70, with the hypothesis that this interaction could be
regulated by Dyn2 binding. Indeed, Vav1 coimmunoprecipitated
with Hsc70 in DanG cells (Figure 7A). Most striking was the 5-fold
increase in the interaction between Vav1 and Hsc70 when Dyn2
was depleted by siRNA, suggesting that Dyn2 prevents the
binding of Hsc70 to Vav1. To determine whether this was an
effect of Dyn2 binding, we expressed the Vav1 WWYY mutant,
which cannot bind Dyn2 or WT Vav1 in Panc1 cells. Again,
Vav1 coimmunoprecipitated endogenous Hsc70, and notably,
the WWYY mutant had a 5-fold increase in binding compared
with WT Vav1 (Figure 7B). In both cases, the increase in Hsc70
binding corresponds to the increased lysosomal degradation
of Vav1 when Dyn2 association is prevented.
If Hsc70 binding is necessary for targeting Vav1 to the lyso-
some, we predicted that disruption of Vav1/Hsc70 bindingwould
block the degradation of Vav1 when it could not bind Dyn2.
Hsc70 targets proteins for lysosomal degradation through
recognition of a loosely conserved ‘‘KFERQ’’ motif, which
consists of a pentapeptide containing (in any order) a basic
residue, an acidic residue, a bulky hydrophobic residue, another580 Developmental Cell 24, 573–585, March 25, 2013 ª2013 Elsevierone of these three residues, and a glutamine at the N or C
terminus (Kaushik and Cuervo, 2012). Vav1 contains multiple
potential Hsc70-binding motifs. Using site-directed mutagen-
esis, we identified one particular motif (762 QFPFKE 767) that,
when mutated (QF 762/763 to AA, or ‘‘QFAA’’), reduced binding
to Hsc70 by nearly 80% (Figures 7C and 7D). Although this motif
is not a perfect match for the previously described KFERQmotif,
it does contain all of the essential elements for Hsc70 binding as
described above. Importantly, this mutation also resulted in
dramatically increased Vav1 protein levels compared with the
Vav1 WWYY mutant, even though the constructs were tran-
scribed at comparable levels (Figures 7E and S3H), and
rendered Vav1 WWYY insensitive to CQ treatment (Figure S3I).
Therefore, blocking Hsc70 binding is sufficient to restore Vav1
stability.
Hsc70 is known to target proteins for lysosomal degradation
through CMA, which requires the lysosomal transmembrane
protein Lamp2a. To determine whether Vav1 degradation is
dependent upon Lamp2a and, in turn, CMA, we tested whether
siRNA-mediated depletion of Lamp2a results in elevated levels
of Vav1 when Dyn2 is reduced by siRNA. Panc04.03 cells were
transfected with siRNAs targeting Dyn2 and Lamp2a, or a control
siRNA, and then Vav1 levels were assessed by immunoblotting.
Indeed, knockdown of Lamp2a resulted in a marked rescue of
Vav1protein levels (Figure7F). Taken together, thesedata strongly
suggest that, in the absence of Dyn2 binding, Vav1 is targeted for
lysosomal degradation through Hsc70 binding and CMA.Inc.
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Depleted of Dyn2
The observations described above underscore the importance
of a Dyn2-Vav1 interaction in Vav1 stability (Figure 5), Rac1
activity, lamellipod extension, and cell motility (Figure 4). From
these findings we postulated that overexpression of Vav1 in
Dyn2 knockdown cells should overcome the loss of Vav1 protein
stability and therefore rescue the defects in these processes. To
test this, we depleted Panc04.03 cells of Dyn2 using siRNA and
overexpressed Vav1 using a lentiviral system. As described
above, transwell cell migration was reduced by 50% upon
Dyn2 knockdown (Figure S4A). Strikingly, re-expression of
Vav1 in the Dyn2 knockdown cells completely rescued the
defects in cell migration, showing that overcoming the loss of
Vav1 protein stability restores Dyn2-dependent migration (Fig-
ure S4A). Similarly, stabilization of Vav1 WWYY by inhibition of
Hsc70 binding also rescued cell migration (Figure 7G). These
data are important because they suggest that Vav1 protein levels
are regulated downstream of Dyn2, and indicate that the primary
mechanism by which Dyn2 regulates Rac1 activity and invasive
cell migration in pancreatic cancer cells is through modulation of
Vav1 protein levels.
If this is true, we predicted that depletion of Dyn2 should have
no effect on Rac1 activation in pancreatic cancer cells that do
not express Vav1. To test this, Dyn2 was knocked down in
Panc1 cells, which do not express Vav1, and Rac1 activation
was measured by GST-PBD pull-down. As predicted, Dyn2
depletion did not inhibit Rac1 activation in Panc1 cells, further
indicating that the effects of Dyn2 on Rac1 signaling are medi-
ated through Vav1 (Figures 7H and S4B). We also predicted
that expression of the Dyn2 D800-811 mutant should not affect
Rac1 activation in cells that do not express Vav1. To examine
this issue, we transfected Panc1 cells with WT Dyn2 or Dyn2
D800-811 and then tested for Rac1 activation and lamellipod
formation as described above. In Panc1 cells, in contrast to
DanG, Panc04.03, or HPAF-II cells that do express endogenous
Vav1 (Figure S1A), expression of either WT Dyn2 or Dyn2 D800-
811 had no effect on Rac1 activation (Figures 7I and S4C). Over-
expression of Dyn2 did increase the percentage of Panc1 cells
forming lamellipodia (Figures 7J and S4D), but this was not in-
hibited by Dyn2 D800-811. These data show that Dyn2 mediates
Rac1 activation through Vav1, and that the inhibitory effects of
Dyn2 D800-811 are also due to regulation of Vav1. Taken
together, these data suggest that a physical interaction with
Dyn2 controls Vav1 stability to regulate Rac1-mediated lamelli-
pod formation and tumor cell migration.
DISCUSSION
In this study, we provide evidence that the large GTPase
Dyn2 regulates the small GTPase Rac1 to potentiate the inva-
sive migration of pancreatic tumor cells. Dyn2 plays an essen-
tial role in regulating Rac1-mediated pancreatic tumor cell
migration through modulation of the Rac1 activator Vav1 via
a direct interaction. Surprisingly, this interaction is required
to maintain Vav1 protein stability, because this GEF is turned
over rapidly by the lysosome in the absence of Dyn2, leading
to decreased Rac1 activation, lamellipod formation, and cell
migration.DeveloAn Enzymatic versus Adaptor Role of Dyn2 in Regulating
Tumor Cell Migration
Dyn2 has been proposed to regulate the activity of Rac1 indi-
rectly by promoting its endocytosis and trafficking. Rac1 is inter-
nalized and activated on early endosomes, and is then recycled
back to the plasma membrane to ensure its localization to the
leading edge, promoting the formation of migratory lamellipodia.
This process is disrupted by expression of dominant-negative
Dyn2 (Dyn2 K44A), which has been shown to inhibit endocytosis,
perturb the localization of active Rac1, and attenuate the forma-
tion of lamellipodia (Palamidessi et al., 2008; Schlunck et al.,
2004). In support of this model, disruption of Dyn2 enzymatic
activity using Dynasore also inhibits lamellipod formation and
tumor cell migration (Eppinga et al., 2012; Yamada et al.,
2009). Interestingly, although expression of Dyn2 K44A disrupts
Rac1 localization and downstream effects, it does not inhibit the
activation of Rac1 under normal conditions, but does inhibit
Rac1 activation induced by the overexpression of Rab5 (Palami-
dessi et al., 2008; Schlunck et al., 2004). In other model systems,
RNA-interference-mediated depletion of Dyn2 inhibits growth-
factor-induced Rac1 activation (Feng et al., 2011; Singleton
et al., 2007). Thus, there is no clear role for Dyn2 in regulating
the biochemical activation of Rac1.
However, we demonstrate here that Dyn2 can directly regulate
Rac1 activation through Vav1 in a manner that is independent of
its enzymatic function, highlighting a role for Dyn2 in regulating
cell migration. In Vav1-expressing cells, depletion of Dyn2 or
expression of a mutated form of Dyn2 that cannot bind Vav1
reduced Rac1 activation by 50%. We found that mutations that
disrupt Dyn2-Vav1 binding had no effect on endocytosis, indi-
cating that the effects on Rac1 signaling and cell migration are
distinct from Dyn2’s enzymatic function, and instead are due
to regulation of Vav1 protein stability. Further, inhibition of
Dyn2 enzymatic activity through a dominant-negative mutation
(K44A) or by treatment with pharmacological inhibitors of Dyn2
had no effect on Vav1 protein stability, demonstrating that this
stabilization is not regulated by Dyn2 enzymatic activity or indi-
rectly through endocytic events. Therefore, this study identifies
an additional mechanism by which Dyn2 can regulate Rac1.
The enzymatic activity of Dyn2 requires both binding to phos-
pholipids and assembly into polymers (Hinshaw, 2000). It is not
known whether the lipid-binding or oligomerization properties
of Dyn2 are required for its endocytosis-independent functions,
including cytoskeletal remodeling and Vav1 stabilization. Further
structural studies of Dyn2will be useful for determining the role of
the multiple functional domains of Dyn2 in tumor cell migration.
Because Vav1 expression is restricted to hematopoietic cells
and some tumor cells, the mechanism described here is also
specific to Vav1-positive cells. Indeed, this may be one reason
why previous studies did not demonstrate a definitive effect of
Dyn2 on Rac1 activation, as the cells used in those studies did
not express Vav1. Because Dyn2 promotes lamellipodia forma-
tion and cell migration even in the absence of Vav1 (Eppinga
et al., 2012; Schlunck et al., 2004), it is assumed that Dyn2 can
enhance migration in both neoplastic and normal cells by
Vav1-independent mechanisms as well. In addition to regulating
Rac1 localization indirectly through endocytosis, as described
above, it is possible that Dyn2 can contribute to tumor cell migra-
tion through interactions with other GEF proteins that regulatepmental Cell 24, 573–585, March 25, 2013 ª2013 Elsevier Inc. 581
(legend on next page)
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pod formation and cell migration by an interaction with a variety
of actin-binding proteins, including cortactin (Kruchten and
McNiven, 2006; Schafer, 2004), or by a direct interaction with
actin itself (Gu et al., 2010). Finally, Dyn2 is known to participate
in remodeling of the extracellular matrix, which is also an impor-
tant component of cell migration (Baldassarre et al., 2003; Ez-
ratty et al., 2005; Wang et al., 2011). Regardless of these addi-
tional mechanisms, many pancreatic tumors, and perhaps
other tumor types, overexpress both Vav1 and Dyn2, which
can synergize to regulate Rac1-mediated cell migration. Indeed,
we found that a significant percentage of human pancreatic
cancer tumors were upregulated for both Vav1 and Dyn2 (Table
S1). Human samples were deidentified and used under the
guidelines and supervision of the Mayo Clinic Institutional
Review Board.
Regulation of Vav1 Function by Modulating Protein
Stability
Modulation of the Vav1 protein level is a potent mechanism to
regulate signaling and cell fate. The data presented here demon-
strate the potent effects of Vav1 overexpression or siRNA-medi-
ated knockdown on Rac1 activation and cell migration in tumor
cells. To date, several mechanisms regulating Vav1 protein
stability have been reported. First, ubiquitination of Vav1 by the
E3 ligase Cbl results in degradation of Vav1 by the proteasome,
thereby inhibiting Vav1-dependent signaling (Bustelo et al.,
1997; De Sepulveda et al., 2000; Miura-Shimura et al., 2003).
Second, proteolytic cleavage of Vav1 by caspases occurs during
both T cell anergy and apoptosis, thereby regulating down-
stream signaling during these processes (Hofmann et al., 2000;
Puga et al., 2008). Third, calpain cleavage of Vav1 appears to
play a role in signaling during platelet aggregation (Miyakawa
et al., 1997). In this study, we define a surprising pathway that
regulates Vav1 turnover. In the absence of Dyn2 binding, Vav1
is targeted for degradation not by the proteasome, as might be
predicted for a cytosolic protein, but by the lysosome, which is
utilized for degradation of endocytosis proteins and in
autophagy.
How does Vav1, a cytosolic protein, gain access to the
membrane-bound lysosome for degradation? Several mecha-
nisms have been implicated in this process, including chap-
erone-associated selective macroautophagy, microautophagy,Figure 7. Dyn2 Protects Vav1 from Hsc70-Mediated Degradation
(A) DanG cells were transfected with control siRNA or siRNA targeting Dyn2, and
(B) Panc1 cells were transfected with empty vector, WT Vav1, or Vav1 WWYY, a
(C) Identification of an Hsc70 binding motif in Vav1. Residues QF 762/763 were
(D) Panc1 cells were transfectedwith empty vector, Vav1WWYY, or Vav1WWYYQ
graphs, coprecipitated Hsc70 was normalized to immunoprecipitated Vav1 and
(E) Panc1 cells were transfected with equal amounts of cDNA for the indicated c
(F) Panc04.03 cells were transfected with siRNAs targeting Dyn2 and Lamp2a to
(G) Panc1 cells were transfected with the indicated constructs and seeded in a tra
by DAPI stain and normalized to vector-transfected cells.
(H) Panc1 cells were transfected with a control siRNA or siRNA against Dyn2, an
(I) Panc1 cells were transfected with empty vector (vec), WT Dyn2, or Dyn2D800-8
(H) and (I), graphed data represent active Rac1/total Rac1 normalized to control
(J) Panc1 cells were transfected with empty vector (vec), WT Dyn2, or Dyn2 D800
shows the percentage of cells that formed lamellipodia.
All graphs represent the mean ± SEM of at least three independent experiments. *p
Develoand CMA. A factor implicated in all three of these pathways is
the chaperone Hsc70 (Arndt et al., 2010; Kaushik and Cuervo,
2012; Sahu et al., 2011). Here, we identified an interaction
between Vav1 and Hsc70, and found that this interaction is
required for the degradation of Vav1. Vav1 WWYY is highly
unstable, but its protein levels are markedly restored when its
putative Hsc70 binding motif is disrupted. This motif appears
to reside within the linker situated between the Vav1 SH2 and
SH3 domains. We propose that as Dyn2 binds to Vav1 via the
SH3 domain, Dyn2 binding physically restricts the access of
Hsc70 to its binding motif, thereby preventing lysosomal target-
ing and degradation of Vav1. This would explain why expression
of the isolated PRD is not sufficient to prevent Vav1 degradation:
it is not bulky enough to block access of Hsc70 to Vav1. Because
the proto-oncogene Vav1 has potent transforming andmigratory
effects, regulation of its turnover is highly relevant in both tumor
cells and normal hematopoietic cells.
The role of Hsc70 in selective lysosomal degradation is best
established in CMA. In this process, which is generally upregu-
lated during cellular stress, Hsc70-bound cargo is imported
into the lysosome in an unfolded state via a Lamp2a channel
(Kaushik and Cuervo, 2012). Often the KFERQ Hsc70-binding
motif is masked by the tertiary structure of the protein and is re-
vealed upon conformation change, posttranslational modifica-
tion, or misfolding, resulting in increased Hsc70 binding and
lysosomal degradation. Our data suggest that Dyn2 may regu-
late the accessibility of an Hsc70-binding motif on Vav1, and
that Vav1 can be degraded via CMA. Interestingly, selective au-
tophagic processes may be aberrantly regulated in cancer cells
(Mizushima et al., 2008; Welsch et al., 2010). Thus, even in the
absence of activating, oncogenic mutations in Vav1, misregula-
tion of pathways that regulate Vav1 stability may have the same
biological consequence, leading to an upregulation of Vav1
expression and subsequent Rac1-mediated invasive cell
migration.
Interestingly, the Hsc70-binding motif in Vav1 (QFPFKE) is not
a perfect match for the consensus Hsc70-binding motif,
because it contains a proline in the middle of the pentapeptide.
The presence of a proline has been shown to be disruptive for
Hsc70 binding. Our data suggest there may be additional flexi-
bility in the already highly variable Hsc70-binding motif. Alterna-
tively, although our data indicate that disruption of the QFPFKE
motif reduces Hsc70 binding, it is possible that this representsthen immunoprecipitated for Vav1 and blotted for Hsc70.
nd lysates were immunoprecipitated for Vav1 and blotted for Hsc70.
mutated to AA (QFAA).
FAA, and lysateswere immunoprecipitated for Vav1 and blotted for Hsc70. For
compared with control cells.
onstructs, and lysates were immunoblotted for Vav1 or actin.
inhibit CMA, and Vav1 levels were normalized to actin.
nswell migration assay for 16 hr. The number of migrating cells was determined
d Rac1 activation was assessed by GST-PBD pull-down.
11 and subjected to a GST-PBD pull-down to assess Rac1 activation. For both
cells.
-811, serum starved, and stimulated with EGF (50 mg/ml) for 20 min. The graph
< 0.05, **p < 0.01; ns, no statistically significant difference. See also Figure S4.
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with Hsc70 via a modified mechanism. Finally, Vav1 degradation
may also be regulated by additional mechanisms. Although Vav1
WWYY stabilization is increased significantly upon the QFAA
mutation to inhibit Hsc70 binding, it is not restored to the levels
of WT Vav1. It is possible that additional KFERQ-like motifs on
Vav1 are able to compensate for the mutation of the QFPFKE
motif, allowing some degradation to continue. In addition, the
WWYY mutation represents a disruption of the Vav1 C-terminal
SH3 domain, which has also been shown to interact with several
proteins, including zyxin, RNA-binding proteins such as Sam68,
and transcriptional regulators (Katzav, 2009). Thus, the stability
of this Vav1 construct may also be regulated by other binding
partners. Regardless, our data demonstrate that the levels of
Vav1 are regulated by its degradation through an Hsc70-chap-
erone-mediated targeting to the lysosome.
In pancreatic cancer, aberrant Vav1 expression is due to
promoter demethylation and transcriptional upregulation (Fer-
nandez-Zapico et al., 2005). In addition, our data demonstrate
that Vav1 interaction with Dyn2 promotes Vav1 stability at the
protein level. Because Dyn2 is also upregulated in pancreatic
cancers, our data raise the intriguing possibility that once Vav1
expression is transcriptionally induced in pancreatic cancer
cells, high levels of Dyn2 can further stabilize Vav1 in tumors,
thereby potentiating the effects of Vav1 overexpression and
further increasing tumor cell survival, proliferation, and metas-
tasis. Therefore, pharmacological agents that target Vav1 or its
interaction with Dyn2 could be potent inhibitors of tumor cell
migration.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfections
DanG, Panc1, and MiaPaCa2 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) + 10% fetal bovine serum (FBS), Panc04.03 cells
were maintained in RPMI + 15% FBS, and HPAF-II cells were maintained in
MEM + 10% FBS. All cells were grown in the presence of 100 U/ml penicillin
and 100 mg/ml streptomycin. The transfection procedures are described in
the Supplemental Experimental Procedures.
Immunoprecipitation, GST Pull-Downs, and Immunoblotting
Cells were lysed and subjected to immunoprecipitation as described in
Supplemental Experimental Procedures. For protein turnover experiments,
cells were treated with 50 mM CHX for 0–6 hr prior to lysis. For lysosomal inhi-
bition, cells were incubated with 25 mM CQ for 48 hr. Primary antibodies were
used as indicated in Supplemental Experimental Procedures.
Migration and Lamellipodia Formation Assays
Transwell migration assays were performed as described previously (Eppinga
et al., 2012), with modifications as described in Supplemental Experimental
Procedures. To measure the formation of lamellipodia, cells were serum
starved overnight, then stimulated with EGF (50 ng/ml; Sigma Aldrich, St.
Louis, MO) for 20 min, and fixed, stained, and imaged as described in Supple-
mental Experimental Procedures.
Immunofluorescence Imaging
Immunofluorescence imaging was performed as described in Supplemental
Experimental Procedures. For lysosomal localization, DanG cells were co-
transfected with mCherry-Vav1 (WT or WWYY) and GFP-Lamp1, and
were fixed and imaged after 48 hr. The number of GFP-Lamp1-positive
vesicles per cell containing mCherry Vav1 or mCherry Vav1 WWYY was
counted. At least 25 cells were scored in each of three independent
experiments.584 Developmental Cell 24, 573–585, March 25, 2013 ª2013 ElsevierSUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.devcel.2013.02.010.
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